Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Income from Continuing Operations (2016 - 2026)

Collegium Pharmaceutical has reported Income from Continuing Operations over the past 10 years, most recently at 16963000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 35.31% year-over-year to 16963000.0; the TTM value through Dec 2025 reached 62870000.0, down 9.13%, while the annual FY2025 figure was 62870000.0, 9.13% down from the prior year.
  • Income from Continuing Operations for Q4 2025 was 16963000.0 at Collegium Pharmaceutical, down from 31507000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 72843000.0 in Q2 2021 and troughed at 25034000.0 in Q4 2021.
  • A 5-year average of 11336500.0 and a median of 12259500.0 in 2024 define the central range for Income from Continuing Operations.
  • On a YoY basis, Income from Continuing Operations climbed as much as 7577.45% in 2021 and fell as far as 459.79% in 2021.
  • Year by year, Income from Continuing Operations stood at 25034000.0 in 2021, then soared by 71.24% to 7199000.0 in 2022, then surged by 543.67% to 31940000.0 in 2023, then plummeted by 60.75% to 12536000.0 in 2024, then skyrocketed by 35.31% to 16963000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for COLL at 16963000.0 in Q4 2025, 31507000.0 in Q3 2025, and 11983000.0 in Q2 2025.